All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-03-28T16:51:04.000Z

What factors contribute to resistance to BCMA-targeted CAR T-cell therapies in multiple myeloma?

Featured
Mar 28, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.

Bookmark this article

During the 6th European CAR T-cell Meeting of the European Hematology Association and European Society for Blood and Marrow Transplantation, the Multiple Myeloma Hub spoke to Paola Neri, University of Calgary, Calgary, CA. We asked, What factors contribute to resistance to B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapies in multiple myeloma?

What factors contribute to resistance to BCMA-targeted CAR T-cell therapies in multiple myeloma?

In this interview, Paola Neri discusses the factors associated with either a lack of response to BCMA-targeted CAR T-cell therapies or loss of response over time, going on to offer insight into the management strategies for these patients. Neri highlights key issues of antigen escape, mutation of BCMA, as well as T-cell exhaustion; she closes with the additional considerations required for difficult-to-treat forms of multiple myeloma, such as extramedullary disease.1,2,3

  1. Lee H, Ahn S, Maity R, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29(9):2295-2306. DOI: 1038/s41591-023-02491-5.
  2. Friedrich M, Neri P, Kehl N, et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 2023;41(4):711-725.e6. DOI: 1016/j.ccell.2023.02.008.
  3. Dhodapkar K, Cohen A, Kaushal A, et al. Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma. Blood Cancer Discov. 2022;3(6):490-501. DOI: 1158/2643-3230.BCD-22-0018.

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
16 votes - 16 days left ...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox